Of some concern with medication and bulimia is the potential seizure inducing risk of Wellbutrin. Because both bulimia and Wellbutrin have been associated with seizures, in general the use of Wellburtin in patients who have bulimia presents significant risk. It is not fully clear whether this risk is theoretical or has been experienced by a significant number of patients with bulimia, as studies of this question are not available. Given the theoretical risk, we try to avoid this combination whenever possible. There is also a small literature on the use of stimulants in patients with bulimia. These remain case reports and we await more thorough studies on this question. Again, given the potential seizure risk of stimulants, they should be used with caution.
A side note needs to be made concerning Topamax, which has been suggested by some clinicians as being an effective treatment for bulimia. To date, studies have not shown Topamax to be superior to an SSRI. Topamax may be associated with paresthesia (tingling) and cognitive impairment. Although Topamax has been reported to have effects on weight, the literature does not support using Topamx for weight issues with bulimia.
Walsh, B. T., Wilson, G. T., Loeb, K. L., Devlin, M. J., Pike, K. M., Roose, S. P., Fleiss, J., &
Waternaux, C. (1997). Medication and psychotherapy in the treatment of bulimia nervosa.
The American Journal of Psychiatry, 154:4, 523 - 531.
Next week: What does it mean to be in recovery?
Contributions by Sarah Emerman